White Guide and Orange Guide Formatting Project - Pfizer
White Guide and Orange Guide Formatting Project - Pfizer
White Guide and Orange Guide Formatting Project - Pfizer
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Use of Disclaimers<br />
<strong>Orange</strong> <strong>Guide</strong> – Chapter 5: Interactions with Health Systems <strong>and</strong> Medical Groups<br />
Be sure to include appropriate disclaimers on all customer presentations. All slides should contain<br />
appropriate confidentiality language in the footer on each slide. Additionally, the following disclaimer<br />
should be prominently displayed up front on a separate slide on all customer presentations:<br />
This presentation represents a potential strategic vision. Strategies/ proposals contained herein<br />
are NOT necessarily endorsed by <strong>Pfizer</strong> senior management <strong>and</strong> are not intended to be<br />
implemented without further review. All cost savings or metrics are estimates based upon publicly<br />
available information <strong>and</strong> should not be construed as guarantees or validation of savings.<br />
Strategies contained herein are subject to Regulatory <strong>and</strong> Legal review <strong>and</strong> approval before<br />
implementation.<br />
Product Messaging Risks<br />
Colleagues underst<strong>and</strong> well that when mentioning a <strong>Pfizer</strong> product by name to a customer, any<br />
statements they make can expose the company to a risk of inappropriate promotion. However,<br />
colleagues often mistakenly believe that as long as they do not mention <strong>Pfizer</strong> products by name <strong>and</strong><br />
only talk “above br<strong>and</strong>,” i.e., just about disease states, they are not at risk of promoting <strong>Pfizer</strong> products<br />
inappropriately. However, as a representative of <strong>Pfizer</strong> charged with driving <strong>Pfizer</strong> business, you may<br />
be at risk of inappropriate promotion in certain cases even when not mentioning a <strong>Pfizer</strong> product. For<br />
example, discussing with a customer disease areas where <strong>Pfizer</strong> does not yet have an approved<br />
product, <strong>and</strong>/or therapeutic areas that are broader than those where <strong>Pfizer</strong> has indications with<br />
approved products, may present a risk of inappropriate promotion.<br />
Do not discuss with a customer a product or disease state unless you have completed the required<br />
training on that product or a disease state. If you discuss a product or disease state you are not<br />
familiar with, you risk inadvertently making (or implying) a statement that is not consistent with<br />
<strong>Pfizer</strong>’s approved messaging.<br />
104<br />
Rev. 09/12<br />
Page 9 of 18
Change language